RUNX1T1 and acute myeloid leukemia: Our data suggest that HMGN1 increases chromatin accessibility to acetyltransferases such as CBP/p300, enhancing the leukemogenic activity of AML oncogenes such as t(8;21)/AML1-ETO that are known to act via histone acetylation.